Zepbound holds FDA approval for chronic weight management and is delivered by injection, with no oral version of tirzepatide currently available for either the diabetes or weight-loss indication
It makes you metabolically healthier
Johnson, Parker A
[PMC free article] [PubMed] [Google Scholar] 189.Rosario M, Dirks NL, Milch C, Parikh A, Bargfrede M, Wyant T, et al
Eligible studies evaluated subcutaneous tirzepatide at 5 mg, 10 mg, 15 mg, or a participant-specific MTD, defined as dose escalation to either 10 mg or 15 mg based on tolerability, or semaglutide at 2.4 mg or its own MTD (escalated to 1.7 mg or 2.4 mg based on tolerability)
In the SMART trial, Semaglutide 2.4 mg reduced albuminuria in people with overweight or obesity and CKD without diabetes with 52% reduction in UACR